1Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol of Education Program ( NCEP ) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel Ⅲ ) [J]. JAMA,2001 ;285(9) :2486-97.
7Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases[ J]. N Engl J Med 1989 ;320( 16 ) :1060-8.
8Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes[J]. Diabetes Care,2004;27( Suppl 1 ) :S68-71.
9Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Progran Adult Treatment Panel Ⅲ Guidelines[ J]. J Am Coll Cardiol,2004 ;44( 3 ) :720-32.
1American Diabetes Association(ADA):Management of Dysplipidemia in Adults with Diabetes[J].Diabetes Care, 2003,26:s83-s86.
2Colagiurl S, Best J. Lipid-Lowering therapy in people with type 2 diabetes [J].Current Opinion in Lipidology,2003,617-623.
3Haffner,SM:Management of dyslipidemia in adults with diabetes [J]. Diabetic care, 1998,21:160-178.
4Robins.Cardiovascular disease with diabetes or the metabolic syndrome:Should statins or fibrates be first line lipid therapy?[J].Current Opinion in Lipidology, 2003,14:575-583.
6Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes,other risk factors, and 12 - yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434 - 444.
7Turner RC, Millns H, Neil HA, Stratton TM, Manley SE,Matthews DR, Holman RR: Risk factors for coronary artery disease in non - insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study(UKPDS 23)BMJ 1998;316:823- 828.
8Collins R, Armitage J, Parish S, Sleigh P, Peto R, the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol - lowering with simvastin in 5963 people with diabetes: a randomized placebo - controlled trial. Lancet 2003; 361: 2005- 2016.
9Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R: Effect of recombinant Apo1 Milano on coronary atherosclerosis in patients with acute coronary syndromes; a randomized controlled trial. JAMA 2003; 290: 2292 -2300.
10West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K: The role of circulating glucose and triglyceride concentrations and their interactions with other"risk factors"as determinants of arterial disease in nine diabetic population samples form the WHO multinational study. Diabetes Care 1983; 6: 361 - 369.
